Our results provide evidence of a negative correlation between miR-181c/d expression and their target SIRT1 in patients with a positive outcome and responding to targeted therapies, thus strongly suggesting that miR-181c/d exert their tumor-suppressive action by targeting SIRT1 and thus silencing its pro-tumorigenic functions. The gene discussed is SIRT1; the disease is neoplasm.